On April 29, 2021 Compugen Ltd. (Nasdaq: CGEN), a clinical-stage cancer immunotherapy company and a leader in predictive target discovery, reported that it will present updates on its ongoing Phase 1 clinical trial evaluating COM701, a first-in-class therapeutic antibody targeting PVRIG, in an oral presentation at the American Society of Clinical Oncology (ASCO) (Free ASCO Whitepaper) 2021 Annual Meeting, being held virtually on June 4-8, 2021 (Press release, Compugen, APR 29, 2021, View Source [SID1234578850]).

Schedule your 30 min Free 1stOncology Demo!
Discover why more than 1,500 members use 1stOncology™ to excel in:

Early/Late Stage Pipeline Development - Target Scouting - Clinical Biomarkers - Indication Selection & Expansion - BD&L Contacts - Conference Reports - Combinatorial Drug Settings - Companion Diagnostics - Drug Repositioning - First-in-class Analysis - Competitive Analysis - Deals & Licensing

                  Schedule Your 30 min Free Demo!

Oral Presentation Details:

Title: "COM701 with or without nivolumab: Results of an ongoing phase 1 study of safety, tolerability and preliminary antitumor activity in patients with advanced solid malignancies"

Abstract: 2504

Session: Developmental Therapeutics—Immunotherapy

Date and Time: June 7, 202, 3:00 PM – 6:00 PM EDT

The abstract will be made available by ASCO (Free ASCO Whitepaper) on May 19, 2021, at 5:00 PM EDT on ASCO (Free ASCO Whitepaper).org.

The presentation will be made available on Compugen’s website at www.cgen.com following the conclusion of the presentation.